Critical Questions for Elevating Care: Optimizing Clinical Use of Biologics for Asthma – Live Webcast November 2, 2023 Pretest

To assist us in evaluating the effectiveness of this activity, please complete the following pretest.

Question Title

* 1. Which of the following best describes your profession?

MD/DO

PharmD/RPh

Other (please specify)

Question Title

* 2. Which of the following best describes your specialty?

Allergy

Pulmonology

Internal Medicine/Family Practice/General Practice

Other (please specify)

Question Title

* 3. How confident are you in the management of patients with moderate-to-severe asthma in your practice?

Very confident

Confident

Neutral

Little confidence

No confidence

Question Title

* 4. Evelyn is a 48-year-old woman with uncontrolled asthma. Her current medications include medium-dose ICS-formoterol and SABA prn, which she reports adherence to. She has had one exacerbation requiring hospital admission and a short course of OCS in the past year. She has comorbid CRSwNP and no other notable environmental factors. Biomarker testing reveals IgE = 60 kU/L, EOS = 450 cells/mL, FeNO = 50 ppb. Which of the following would you recommend for her?

Step up to high-dose ICS-formoterol

Start Anti-IL-5

Start Anti-IL-4Ra

Start Anti-TSLP

Question Title

* 5. In a recent retrospective study of asthma patients, which of the following factors was found to be a characteristic of patients who required switching biologics?

Higher blood eosinophil counts

Older age

Lower baseline pulmonary function indices

Question Title

* 6. Jeremy is a 30-year-old man with a history of uncontrolled asthma who began a trial of a biologic therapy 4 months ago. He reports decreased cough and shortness of breath but has recently had an exacerbation requiring a short course of OCS. Which of the following would you recommend?

Continue current biologic trial to assess response after 6-12 months of treatment

Switch to a different biologic

Discontinue the biologic

Question Title

* 7. How does current evidence from real-world studies compare with RCT data on the long-term efficacy of biologic therapies for moderate-to-severe asthma?

Long-term efficacy is similarly sustained in both patient populations

Long-term efficacy is similarly reduced in both patient populations

Long-term efficacy is reduced in real-world vs clinical trial patient populations

Question Title

* 8. In long-term trials of both dupilumab (TRAVERSE) and mepolizumab (COLUMBA), improvements in exacerbations, asthma control, lung function, OCS use, and QOL were sustained with extended treatment of approximately how long?

0 - 1.5 years

1.5 - 2.5 years

2.5 - 3.5 years

>3.5 years

Question Title

* 9. Please complete and submit this survey.

Name:

Email: